NK 081
Alternative Names: NK-081Latest Information Update: 10 Mar 2024
At a glance
- Originator NK CellTech
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Feb 2024 Preclinical trials in Cancer in China (Parenteral), prior to February 2024 (NK CellTech pipeline, February 2024)